Associated Papers
Clinical features and outcomes in primary nervous system histiocytic neoplasms.
Nathoo N et al.
Blood Cancer Journal, 2024
BRAF - a tumour-agnostic drug target with lineage-specific dependencies.
Hanrahan AJ et al.
Nature Reviews. Clinical Oncology, 2024
BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities.
Ciner AT et al.
Molecular Cancer Research : Mcr, 2023
BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences.
Hanrahan AJ et al.
Cancer Research, 2022
Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
Pham NA et al.
Scientific Reports, 2021
Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.
Hendifar A et al.
Jco Precision Oncology, 2021
Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma.
Wrzeszczynski KO et al.
Cold Spring Harbor Molecular Case Studies, 2019
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Aguirre AJ et al.
Cancer Discovery, 2018
Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
Estep AL et al.
Plos One, 2007
Select a paper to view details